EMA Management Board Meets to Discuss New Location
The agency met to discuss its new temporary and permanent premises in Amsterdam.
On Feb. 1, 2018, the Management Board of the European Medicines Agency met to discuss the agency’s future locations in Amsterdam. EMA will move from London to Amsterdam by the end of March 2019 and will move into a temporary residence until its new permanent location can be built.
The permanent location will be a new, tailor-made facility in the business district of Zuidas in Amsterdam. Details on the new, permanent location were given to the agency by the Dutch government. Because the building will not be complete by March 30, 2019, when EMA must relocate, a temporary location must be prepared. The agency stated in a press release that the temporary building, located in the Sloterdijk area, will be refurbished by January 1, 2019
The agency also discussed the dossier that will be submitted to the Budgetary Authority. EMA must gain a positive opinion from the Budgetary Authority before it can enter into a contractual obligation. EMA will gradually relocate staff to Amsterdam by the end of March 2019.
Source: EMA
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
AES Clean Technology Launches Next-Generation OSM Utility Solution for Cleanrooms at INTERPHEX 2025
April 2nd 2025Officially launched at INTERPHEX 2025, the Omni ASCENT is a next-generation off-site manufactured vertical utility solution that offers optimized cleanroom flexibility and efficiency.
